Envoy Medical Enters Material Definitive Agreement
Ticker: COCHW · Form: 8-K · Filed: Jun 25, 2024 · CIK: 1840877
Sentiment: neutral
Topics: material-definitive-agreement, contract
TL;DR
Envoy Medical signed a big deal, details to come.
AI Summary
Envoy Medical, Inc. announced on June 24, 2024, that it entered into a Material Definitive Agreement. The filing does not specify the other party or the terms of the agreement, but it is classified under Item 1.01, which typically relates to significant contracts.
Why It Matters
This filing indicates a significant new contract or partnership for Envoy Medical, which could impact its future business operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the 8-K filing regarding the material definitive agreement introduces uncertainty about its implications.
Key Players & Entities
- Envoy Medical, Inc. (company) — Registrant
- June 24, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement?
The filing does not specify the nature of the Material Definitive Agreement, only that one was entered into on June 24, 2024.
Who is the other party to the Material Definitive Agreement?
The filing does not disclose the identity of the other party involved in the Material Definitive Agreement.
What are the key terms and financial implications of this agreement?
The filing does not provide details on the key terms or financial implications of the Material Definitive Agreement.
When was the Material Definitive Agreement officially entered into?
The Material Definitive Agreement was entered into on June 24, 2024.
Under which item is this Material Definitive Agreement being reported?
This Material Definitive Agreement is being reported under Item 1.01 of Form 8-K.
Filing Stats: 776 words · 3 min read · ~3 pages · Grade level 11.1 · Accepted 2024-06-25 16:15:24
Key Financial Figures
- $0.0001 — tered Class A Common Stock, par value $0.0001 per share COCH The Nasdaq Stock Mar
- $11.50 — A Common Stock at an exercise price of $11.50 per share COCHW The Nasdaq Stock Ma
- $10.46 — Common Stock ") at an exercise price of $10.46 per share. On November 27, 2023, the Co
Filing Documents
- ea0208409-8k_envoy.htm (8-K) — 29KB
- ea020840901ex10-1_envoy.htm (EX-10.1) — 11KB
- 0001213900-24-055739.txt ( ) — 257KB
- coch-20240624.xsd (EX-101.SCH) — 4KB
- coch-20240624_def.xml (EX-101.DEF) — 26KB
- coch-20240624_lab.xml (EX-101.LAB) — 36KB
- coch-20240624_pre.xml (EX-101.PRE) — 25KB
- ea0208409-8k_envoy_htm.xml (XML) — 6KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, on April 17, 2023, Envoy Medical, Inc. (formerly known as Anzu Special Acquisition Corp I) (the " Company ") and Envoy Medical Corporation (" Legacy Envoy ") entered into an agreement (as amended to date, the " Forward Purchase Agreement ") with Meteora Special Opportunity Fund I, LP (" MSOF "), Meteora Capital Partners, LP (" MCP "), Meteora Select Trading Opportunities Master, LP (" MSTO ") and Meteora Strategic Capital, LLC (" MSC " and, collectively with MSOF, MCP and MSTO, the " Meteora FPA Parties ") for an OTC Equity Prepaid Forward Transaction. Pursuant to the terms of the Forward Purchase Agreement, among other things, the Company issued 3,874,394 warrants (the " Shortfall Warrants ") to purchase up to 3,874,394 shares (the " Shortfall Warrant Shares ") of the Company's Class A common stock, par value $0.0001 per share (the " Common Stock ") at an exercise price of $10.46 per share. On November 27, 2023, the Company and the Meteora FPA Parties entered into a Common Stock Purchase Warrant (the " Common Stock Purchase Warrant "), pursuant to which the Company issued to the Meteora FPA Parties Shortfall Warrants to purchase up to 3,874,394 shares of Common Stock. On June 24, 2024, the Company and the Meteora FPA Parties entered into Amendment No. 1 to the Common Stock Purchase Warrant (the " Shortfall Warrant Amendment "). The Shortfall Warrant Amendment provides for the extension of the expiration date of the Shortfall Warrants by six months, from June 30, 2024 to December 31, 2024. The issuance and resale of the Shortfall Warrant Shares and the resale of the Shortfall Warrants have been registered pursuant to the Company's Registration Statement on Form S-1 (File No. 333-276590), which was declared effective by the U.S. Securities and Exchange Commission on May 2, 2024. The foregoing description of the Shortfall Warrant Amendment does not purport to be complete and is qualif
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Exhibit 10.1 Amendment No. 1 to Common Stock Purchase Warrant. 104 Cover Page Interactive Data File (embedded within the XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 25, 2024 ENVOY MEDICAL, INC. By: /s/ David R. Wells David R. Wells Chief Financial Officer 2